Post-transplant lymphoproliferative disorder in paediatric patients: the Irish perspective—a single centre experience
Conclusion
The outcome of paediatric patients treated for PTLD at our institution is at least comparable to published international series and supports the use of rituximab ± low dose chemotherapy in the treatment of this malignancy.
Source: Irish Journal of Medical Science - Category: Journals (General) Source Type: research
More News: Biomedical Science | Cancer & Oncology | Chemotherapy | Children | General Medicine | Pediatrics | Rituxan | Science | Stem Cell Therapy | Stem Cells | Transplants